Phase I/II Study of SCTB39-1 in Advanced Solid Tumours
A phase 1/2 trial of SCTB39-1 in advanced solid tumours, run by Sinocelltech Ltd., now recruiting.
Overview
Phase I/II Study of SCTB39-1 in Advanced Solid Tumours is a phase 1/2 interventional study registered as NCT07050641 by Sinocelltech Ltd., with 110 participants planned, started 2025-06-23 and due to reach its primary completion in 2028-06-30. Interventions recorded: SCTB39-1.
Similar pages
not linked directly; found by shared links- TrialA Study to Evaluate the Efficacy, Safety, and Immunogenicity of SCT1000 in Healthy Women Aged 18-45 Years
Shares Sinocelltech, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialAims to Explore the Safety, Tolerability, and Preliminary Efficacy of SCTB41 in Adult Patients with Advanced Malignant Solid Tumours.
Shares Sinocelltech, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialInvestigation of a Therapeutic Vaccine (ACIT-1) in Cancer
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialPlasmodium Immunotherapy for Advanced Malignant Solid Tumors
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialFirst-in-Human Study of ICT01 in Patients With Advanced Cancer
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA 1/2 Phase Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ASKB589 in Patients With Locally Advanced or Metastatic Solid Tumors
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialPhase 1/2a Study of MPB-1734 in Patients With Advanced Solid Tumors
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Phase I/II Clinical Trial of ICP-723 in the Treatment of Advanced Solid Tumors
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.